Navigation Links
Specific Imbalance Between Two Peptides may Cause Alzheimer's

Researchers at Rensselaer Polytechnic Institute have challenged the current theory on the causes and prevention of Alzheimers disease , suggesting that a specific imbalance between two peptides may be responsible for preventing this form of dementia.

"We have found that two peptides, AB42 and AB40, must be in balance for normal function," said Chunyu Wang, lead researcher and assistant professor of biology at Rensselaer.

"They are like the Yin and Yang in Taiji, an ancient Chinese philosophy. When the peptides are produced in the correct proportions, the brain is healthy; but when that delicate balance is changed, pathological changes will occur in the brain and the persons memories become hazy, leading to eventual dementia," the researcher added.

If Wangs hypothesis turns out to be correct, the addition of AB40 may help stop the diseases development.

He, however, admits that further research is required to prove his hypothesis.

The two peptides identified by Wang have been previously found in deposits, called senile plaques or amyloid plaques, in brains afflicted with Alzheimers disease. These plaques, mainly composed of AB42 fibrils, are a hallmark of Alzheimers disease.

During the study, Wang used the advanced Nuclear Magnetic Resonance (NMR) machines to monitor the formation of harmful AB42 fibrils in the presence of different levels of AB40. He found that as AB40 levels increased, the aggregation of AB42 fibrils sharply decreased, protecting benign AB42 monomers.

"We have found that the ratio of AB40 to AB42 plays a key role in AB42 aggregation," he said.

"The current mode of thinking in Alzheimers emphasises the toxic role of AB42 but neglects the protective role of AB40. Combined with previous work on AB40 by many other groups, our data suggest that AB40 has an equally important, protective role in Alzheimers. Thus AB42, the bad molecule, and AB40, the good molecule, are like Yin and Yang in Taiji. The brain can only function normally when they are in balance," he added.

The study, to be published in the Journal of Molecular Biology, shows that when there is 15 times more AB40 than AB42, the formation of AB42 fibrils is almost completely stopped.

"This means that the introduction of AB40 to tip the peptide balance toward AB40 could potentially halt or slow down the progression of the Alzheimers in the human brain," Wang said.

Wang plans to continue investigating how AB40 halts the formation of AB42 fibrils.

"This has the potential to become a simple therapy to prevent the formation of toxic AB42 species. I plan to continue my research on the role of AB40 and hope that we can test this theory on human neurons, animal models, and someday in clinical trials. One critical advantage of using AB40 for the prevention or therapy for Alzheimers is that AB40 is already known to be largely free of side effects at near physiological concentration," he said.


'"/>




Related medicine news :

1. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
2. Heart Drug Also Effective In Preventing Specific Causes Of Death
3. Specific Changes In A Particular Gene Found To Increase The Risk of Alzheimer’s Diseas
4. New Race –Specific drug
5. Age-Dependent Alterations Not Specific For Alzheimers Disease
6. Developing Specific Skills Ensure Better Grades In US Kids
7. Specific Immune Mechanism against DNA viruses
8. The Publication Of Surgeon Specific Death Rates Raises Controversy
9. Timing of Food Consumption Activates Genes in Specific Brain Area
10. By Targeting Specific Germs, Hospital Hopes to Improve Pneumonia Treatment
11. Complicated Grief Needs Specific Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will ... Diego honoring the 2016 MPN Heroes—eight individuals who have made a difference in the ... beyond the standard of care, demonstrating leadership within the MPN community and/or a commitment ...
(Date:12/2/2016)... CO (PRWEB) , ... December 02, 2016 , ... Advanced ... announced it has appointed Jason Bice, CPA, MBA to serve as Advanced Inc.’s Chief ... for Advanced, Inc. , Jason brings extensive financial and operational leadership experience to ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... The annual ... Enrollment Period (or Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who ... C) or prescription drug plan (Part D) need to make changes during this period ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... ... an inspirational interview of two ostomy patients, standing as living proof that attitude ... suffer from digestive diseases and issues that spike around the holidays. This campaign ...
(Date:12/2/2016)... ... 2016 , ... Mediaplanet is proud to announce the launch ... innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians ... years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Dec. 2, 2016  Eli Lilly and Company (NYSE: ... for 2017 and provide updated financial guidance for 2016 ... a conference call on that day with the investment ... guidance. The conference call will begin at ... can access a live webcast of the conference call ...
(Date:12/2/2016)... bioLytical Laboratories, ein Weltführer bei schnellen Tests für Infektionskrankheiten, hat sein ... eingeführt. Continue Reading ... ... , ... ) bioLytical wurde durch die Clinton Health Access ...
(Date:12/2/2016)... , Dec. 2, 2016 Boston Scientific ... definitive agreement to acquire certain manufacturing assets and capabilities ... (TSX: NVC) advanced biological tissue business, as well as ... of $75 million in cash. The Neovasc advanced biological ... including the Boston Scientific Lotus™ Valve System. * ...
Breaking Medicine Technology: